Delivery Order SPE2DB22D2206-SPE2DB24FHJ35
Award Date
5/22/24
Potential Completion Date
6/13/24
Potential Value
$11K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of HYPERRAB 300 UNIT/ML VIAL 5ML, a pharmaceutical product, to the U.S. Defense Logistics Agency (DLA). The firm-fixed-price, $9,391.75 contract has a completion date of July 1, 2024. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical supplies to DLA facilities...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of HYPERRAB 300 UNIT/ML VIAL 3ML pharmaceutical products. The $44,982.40 firm-fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) on June 26, 2024, with a final completion date of July 18, 2024. The contract does not have a set-aside designation. Amerisourcebergen is a large pharmaceutical distribution company that has been awarded several federal contracts to...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is a Firm Fixed Price Delivery Order to provide HYPERRAB 300 UNIT/ML VIAL 3ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The award, valued at $13,494.72 with a completion date of July 15, 2024, is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, worth up to $999,999,999.00 through December 31, 2025. This single-award IDC serves...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the supply of HYPERRAB 300 UNIT/ML VIAL 3ML pharmaceutical product to the Defense Logistics Agency (DLA). The $1,124.56 firm-fixed price delivery order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 between Amerisourcebergen and the DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical...
This federal contract award to Amerisourcebergen Drug Corporation's Corporate Office division is a Firm Fixed Price Delivery Order from the Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical, valued at $15,026.80. The contract is for the delivery of HYPERRAB 300UNIT/ML 1S, a pharmaceutical product, with a period of performance through May 17, 2024. Amerisourcebergen is a major supplier of pharmaceutical products and medical supplies to the federal government,...
This is a federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division, a subsidiary of Amerisourcebergen Corporation, a major pharmaceutical distribution company. The contract, awarded by the Defense Logistics Agency (DLA) Troop Support Medical, is for the delivery of a specific pharmaceutical product, HYPERRAB 300 UNIT/ML VIAL 5ML. The contract has a ceiling value of $3,677.16 and a completion date of January 12, 2024. This is a firm fixed price delivery order contract....
Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, was awarded a Firm Fixed Price delivery order contract valued at $1,116.57 by the Defense Logistics Agency (DLA) to provide HYPERRAB 300 UNIT/ML VIALML pharmaceuticals. This delivery order is part of a larger Indefinite Delivery Contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary...
This federal contract award, issued by the Defense Logistics Agency (DLA), is a Delivery Order (SPE2DB24FLFU6) valued at $3,756.72 to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a critical pharmaceutical product, with an ultimate completion date of August 21, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 between Amerisourcebergen and the DLA Troop Support Medical,...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order with a firm fixed price of $14,326.40 and a completion date of May 8, 2025. The contract is not set aside and involves the procurement of HYPERRAB 300 UNIT/ML VIAL 5ML, a medical product. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop...
This federal contract award to Amerisourcebergen Drug Corp, Corporate Office Division, is for the supply of a pharmaceutical product, HYPERRAB 300 UNIT/ML VIAL, to the Defense Logistics Agency (DLA). The $4,466.28 firm fixed-price delivery order has a performance period through June 17, 2024. The contract is not designated as a set-aside. Amerisourcebergen, a major pharmaceutical distributor, holds a single-award Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at...